Piramal Enterprises Limited
NSE: PEL · Consumer NBFC
Snapshot
Unlock Piramal Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Piramal Enterprises Limited is a diversified conglomerate operating primarily in financial services and pharmaceuticals. Its financial arm provides housing finance, structured debt, and infrastructure funding, while its pharmaceutical division focuses on contract development, manufacturing, and consumer healthcare products.
Business Model
The company generates revenue through interest income and fees from its diverse lending portfolio in the real estate and infrastructure sectors, alongside the sale of pharmaceutical products and contract manufacturing services. It leverages a distressed asset platform to invest in equity and debt, diversifying its income streams across financial and healthcare markets.
Growth Outlook
Growth is expected to be driven by the expansion of its retail lending portfolio and the scaling of its pharmaceutical contract manufacturing capabilities. The company continues to focus on strengthening its consumer healthcare brand presence and capitalising on distressed asset opportunities.
Key Risks
- Credit Risk. Exposure to the real estate and infrastructure sectors makes the company vulnerable to project delays and borrower defaults.
- Regulatory Risk. The pharmaceutical business is subject to stringent global quality standards and regulatory inspections that could impact manufacturing operations.
- Interest Rate Risk. Fluctuations in interest rates may impact the net interest margins and the cost of borrowing for the financial services division.
- Market Competition. Intense competition in both the NBFC space and the pharmaceutical sector could pressure margins and market share.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Piramal Enterprises Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹10,233 Cr
TTM · consolidated
NET PROFIT
₹580 Cr
TTM · consolidated
EPS
₹25.70
TTM · consolidated
RETURN ON EQUITY
2.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.6%
TTM · consolidated
P/E
43.7x
Q1 FY26 · consolidated
EBITDA MARGIN
65.6%
TTM · standalone
NET PROFIT MARGIN
10.5%
Q1 FY26 · consolidated
Peers · Consumer NBFC
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Piramal Enterprises LimitedPEL | 25,485 | 43.74 | — | 10.4% | 65.6% | 2.2% | 4.6% | — |
Larsen & Toubro Ltd.LT | 4,83,706 | 32.29 | 17.92 | 11.8% | 12.2% | 18.8% | 15.3% | +7.8% |
Grasim Industries Ltd.GRASIM | 1,76,690 | 41.97 | 16.64 | 19.8% | 14.7% | 10.4% | 4.4% | +11.2% |
Cholamandalam Financial Holdings Ltd.CHOLAHLDNG | 25,639 | 12.03 | — | 18.3% | — | 41.4% | — | -25.7% |
As of Q1 FY26
Financials
Piramal Enterprises Limited
NSE: PEL · Consumer NBFC
Snapshot
Unlock Piramal Enterprises Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Piramal Enterprises Limited is a diversified conglomerate operating primarily in financial services and pharmaceuticals. Its financial arm provides housing finance, structured debt, and infrastructure funding, while its pharmaceutical division focuses on contract development, manufacturing, and consumer healthcare products.
Business Model
The company generates revenue through interest income and fees from its diverse lending portfolio in the real estate and infrastructure sectors, alongside the sale of pharmaceutical products and contract manufacturing services. It leverages a distressed asset platform to invest in equity and debt, diversifying its income streams across financial and healthcare markets.
Growth Outlook
Growth is expected to be driven by the expansion of its retail lending portfolio and the scaling of its pharmaceutical contract manufacturing capabilities. The company continues to focus on strengthening its consumer healthcare brand presence and capitalising on distressed asset opportunities.
Key Risks
- Credit Risk. Exposure to the real estate and infrastructure sectors makes the company vulnerable to project delays and borrower defaults.
- Regulatory Risk. The pharmaceutical business is subject to stringent global quality standards and regulatory inspections that could impact manufacturing operations.
- Interest Rate Risk. Fluctuations in interest rates may impact the net interest margins and the cost of borrowing for the financial services division.
- Market Competition. Intense competition in both the NBFC space and the pharmaceutical sector could pressure margins and market share.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Piramal Enterprises Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹10,233 Cr
TTM · consolidated
NET PROFIT
₹580 Cr
TTM · consolidated
EPS
₹25.70
TTM · consolidated
RETURN ON EQUITY
2.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.6%
TTM · consolidated
P/E
43.7x
Q1 FY26 · consolidated
EBITDA MARGIN
65.6%
TTM · standalone
NET PROFIT MARGIN
10.5%
Q1 FY26 · consolidated
Peers · Consumer NBFC
As of Q1 FY26